# Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy

> **NCT02570789** · PHASE4 · TERMINATED · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 90 (actual)

## Conditions studied

- Clear-cell Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** patients with sunitinib or pazopanib

## Key facts

- **NCT ID:** NCT02570789
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2018-12
- **Final completion:** 2021-03-01
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** not enough accrual
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02570789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02570789, "Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02570789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*